A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

Plain-language guide to NCT06704763: phase 1 interventional trial of Orforglipron (Foundayo, non-peptide), 27 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT06704763
Phase: phase 1
Status: completed
Start: 2024-12-06
Completion (planned or actual): 2025-02-05
Participants: 27 (actual)
Design: na, open label (everyone knows who gets what), basic_science
Conditions studied: Healthy
Results posted: yes

What This Study Did, in Plain Language

What Was Tested

This registered phase 1 trial tested Orforglipron (Foundayo, non-peptide).

The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants.

The study will last up to approximately 8 weeks including screening.

It had 1 arm (groups): Midazolam + Orforglipron + Quinidine (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 27 actual participants took part.

It was open to people of any sex aged from 21 years up to 70 years.

Healthy volunteers could join, not only people with the condition.

The full record lists 5 inclusion and 12 exclusion criteria; among the exclusions: have a history of benign ethnic neutropenia; have a history or presence of pancreatitis, including chronic pancreatitis or idiopathic acute pancreatitis; have known allergies to:.

How the Study Was Run

The set-up was single-group and open-label.

Everyone knew when Orforglipron (Foundayo, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2024-12-06 with completion listed for 2025-02-05.

It ran at 1 site in United States.

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: PK: Maximum Observed Concentration (Cmax) of Orforglipron.

It also tracked 4 secondary outcomes, for example PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam, PK: Maximum Concentration (Cmax) of Midazolam, PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam and PK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam.

What This Means in Plain Language

Put simply, this is a phase 1 trial of Orforglipron (Foundayo, non-peptide) in 27 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.

Our Notes on the Compound

Orforglipron (Foundayo, non-peptide): An oral small-molecule GLP-1 receptor agonist (not a peptide); FDA-approved as Foundayo on April 1, 2026 for chronic weight management.

Orforglipron (Foundayo, non-peptide) in the library

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.